Who Regulates US Longevity Clinics in 2026? FDA, State Boards, Compounding, and Off-Label Care
US longevity clinics are not outside regulation, but oversight is split. This map explains FDA product rules, state professional oversight, compounding, off-label care, and what patients can verify.
Review note, August 28, 2026: This article was rebuilt as a regulator map using FDA guidance. It removes unsupported claims that longevity medicine operates in a single regulatory vacuum.
A US longevity clinic may combine conventional preventive care, off-label prescribing, compounded medicines, laboratory testing, imaging, supplements, and wellness services. No single agency evaluates that whole package as one product.
That fragmented structure can be confusing, but it does not mean no rules apply. The useful approach is to identify what is being sold, who is delivering it, and which regulator covers that part of care.
The oversight map
| Question | Primary place to verify | What the check can establish |
|---|---|---|
| Is the clinician licensed and subject to professional discipline? | The relevant state medical or professional board | Licence status, specialty information where available, and public disciplinary actions |
| Is a drug FDA-approved for a particular indication? | FDA drug labelling and databases | Approved product, labelled use, dose, and safety information |
| Is an approved drug being used off-label? | Treating clinician, product label, and informed-consent discussion | The clinical rationale and evidence for a use FDA has not approved |
| Is a medicine compounded? | Prescriber, dispensing pharmacy, state board of pharmacy, and FDA when applicable | Who made it, why compounding was needed, and which oversight pathway applies |
| Is a laboratory test performed by an identified laboratory? | Test report and applicable federal or state laboratory records | Laboratory identity, method, and reference information |
| Is a device or regenerative product authorised? | FDA databases and the named manufacturer | Product identity and regulatory status, rather than a clinic’s category label |
This is a starting map, not legal advice. State law and the facts of a specific service can change which authority has jurisdiction.
FDA approval and off-label prescribing are different questions
An FDA-approved drug has been evaluated for the uses described in its approved labelling. A licensed clinician may generally prescribe that drug for a different use when they judge it medically appropriate. The FDA explains that it has not determined safety and effectiveness for that unapproved use.
For patients, off-label should trigger a better consent conversation, not an automatic verdict. Ask:
- What exact outcome is the treatment intended to improve?
- What human evidence supports this use, dose, and duration?
- What approved or non-drug alternatives exist?
- Which adverse effects and interactions will be monitored?
- What are the stop criteria?
Compounded drugs do not receive FDA premarket approval
The FDA compounding Q&A states that compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before they are marketed.
The same guidance explains that state boards of pharmacy generally provide day-to-day oversight of state-licensed pharmacies that are not registered outsourcing facilities. FDA uses risk-based inspection for outsourcing facilities registered under section 503B and may inspect other compounding operations.
Compounding can serve a real patient need, such as when an approved medicine cannot be used in its available formulation. Poor compounding can also cause contamination or incorrect strength. The clinic should identify the pharmacy, formulation, lot, storage requirements, and reason an approved product does not meet the patient’s need.
Cell and tissue claims need product-level verification
The word regenerative does not establish an FDA status. The agency warns that many regenerative products have been marketed without approval and reports harms including infections, tumours, and blindness.
The FDA’s compounding guidance also states that biologics cannot be compounded under sections 503A or 503B. Registration of a study on ClinicalTrials.gov is not proof that a product is approved or can be marketed legally.
Ask for the exact product name, manufacturer, FDA status, clinical-trial identifier when relevant, and the clinician responsible for follow-up. A phrase such as stem-cell protocol is not enough to perform that check.
Five records a clinic should provide
Before paying for a medical intervention, request:
- The responsible clinician’s full name, licence state, and role.
- The diagnosis or risk finding that supports the recommendation.
- The product, device, laboratory, or imaging protocol by name.
- A consent document that distinguishes approved, off-label, compounded, and investigational components.
- A monitoring and adverse-event plan, including who receives results after the visit.
US longevity care is regulated component by component. That makes transparent documentation more important, because a premium package name does not tell a patient which rules or evidence apply inside it.
Main source: FDA, Compounding and FDA: Questions and Answers, reviewed August 28, 2026. Patients can locate the relevant licensing authority through the Federation of State Medical Boards directory.